Cytosorbents Crescita futura
Criteri Future verificati 3/6
Si prevede che Cytosorbents aumenterà gli utili e i ricavi rispettivamente del 77.3% e 11.1% all'anno, mentre si prevede che l'EPS crescerà del 78.4% all'anno.
Informazioni chiave
77.3%
Tasso di crescita degli utili
78.43%
Tasso di crescita dell'EPS
| Medical Equipment crescita degli utili | 16.1% |
| Tasso di crescita dei ricavi | 11.1% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 21 May 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento della narrazione • May 15
CTSO: ICU Utilization And Nasdaq Compliance Extension Will Support Future Upside
Analysts have kept the fair value estimate for Cytosorbents steady at $0.75. Modest tweaks to assumptions for the discount rate, revenue growth, profit margin, and future P/E reflect updated views on risk, earnings power, and likely valuation multiples.Aggiornamento della narrazione • Apr 27
CTSO: ICU Adoption And Nasdaq Compliance Efforts Will Support Future Upside
Analysts have maintained their $0.75 price target on Cytosorbents. They cite small adjustments in the discount rate, revenue growth assumptions, and future P/E estimates as they refine their models, while keeping their overall valuation view unchanged.Aggiornamento della narrazione • Apr 11
CTSO: 2025 Revenue Outlook And ICU Adoption Will Support Upside
Analysts have maintained their $0.75 price target for Cytosorbents, citing only modest adjustments to assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock’s valuation. What's in the News Nasdaq granted CytoSorbents a 180 day extension, until September 28, 2026, to regain compliance with the US$1.00 minimum bid price requirement for continued listing on the exchange, with the stock remaining listed during this period (Delistings notice).Aggiornamento della narrazione • Mar 28
CTSO: Steady 2025 Outlook And ICU Therapy Progress Will Support Upside
Analysts have held their fair value estimate for Cytosorbents steady, keeping the implied price target unchanged at $0.75. This reflects slightly adjusted views on discount rate, revenue growth and profit margin assumptions, without a clear shift in overall conviction.Aggiornamento della narrazione • Mar 12
CTSO: Steady 2025 Revenue Guidance Will Support Measured Long Term Upside
Analysts have made a modest adjustment to their Cytosorbents price target, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Taken together, these changes leave their fair value estimate broadly unchanged around $0.75.Aggiornamento della narrazione • Feb 26
CTSO: Flat 2025 Outlook And Cost Discipline Will Support Measured Upside
Analysts have slightly adjusted their price target for Cytosorbents to reflect updated assumptions around revenue growth, profit margin and future P/E, while keeping the fair value broadly in line at $0.75. What's in the News Cytosorbents issued earnings guidance for the fourth quarter of 2025, with revenue expected to be approximately US$9.2 million, the same figure as guidance for the fourth quarter of 2024 (Key Developments).Aggiornamento della narrazione • Feb 09
CTSO: Cost Cuts And 2026 Cash Flow Break Even Will Support Upside
Analysts have trimmed their price target on Cytosorbents to reflect a slightly lower assumed discount rate, marginally higher projected revenue growth, improved profit margin expectations, and a modestly lower future P/E multiple. This results in a revised valuation that they see as better aligned with updated assumptions.Aggiornamento della narrazione • Jan 26
CTSO: Cost Cuts And 2026 Cash Flow Break Even Will Shape Outlook
Narrative Update on Cytosorbents Analysts have kept their price target for Cytosorbents steady at US$0.75, citing updated assumptions that reflect slightly lower discount rates, modestly higher projected revenue growth, a stable profit margin outlook, and a small adjustment to expected future P/E levels. What's in the News Cytosorbents issued earnings guidance for the fourth quarter of 2025, with revenue expected to be approximately US$9.2 million, in line with the fourth quarter of 2024 at US$9.2 million (Key Developments).Aggiornamento della narrazione • Jan 10
CTSO: Cost Reductions And 2026 Cash Flow Break Even Will Support Upside
Analysts have updated their price target on Cytosorbents and maintained fair value at US$0.75. They have also fine tuned underlying assumptions such as the discount rate, revenue growth, profit margin and future P/E to reflect revised views on the company’s risk and earnings profile.Aggiornamento della narrazione • Dec 26
CTSO: Cost Cuts And Nasdaq Listing Risk Will Shape Balanced Outlook
Analysts modestly raised their price target on Cytosorbents to reflect a slightly lower discount rate and higher expected future earnings multiples, even as they tempered long term revenue growth assumptions. What's in the News Cytosorbents announced a strategic workforce and cost reduction plan, cutting approximately 10% of its staff and realigning production and operating expenses to target operating cash flow break even by the first quarter of 2026 (Key Developments).Aggiornamento della narrazione • Dec 12
CTSO: Workforce Cuts And FDA Pathway Are Expected To Shape Outlook
Analysts have trimmed their price target on Cytosorbents from approximately 12.84 dollars to 7.96 dollars. This reflects slightly lower long term revenue growth assumptions, a higher perceived risk profile, and only modestly improved profitability expectations.Articolo di analisi • Nov 13
Market Cool On Cytosorbents Corporation's (NASDAQ:CTSO) Revenues Pushing Shares 31% Lower
To the annoyance of some shareholders, Cytosorbents Corporation ( NASDAQ:CTSO ) shares are down a considerable 31% in...Articolo di analisi • Nov 08
Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Aggiornamento della narrazione • Aug 10
FDA And Health Canada Approval Will Spur ICU Solutions
Cytosorbents’ consensus price target has been raised from $5.00 to $7.00, reflecting improved profitability with net profit margin rising to 12.34% and a more attractive future P/E of 74.11x. What's in the News New studies demonstrate early and intensive CytoSorb® therapy significantly improves clinical outcomes for sepsis and septic shock patients, with peer-reviewed data showing increased survival rates when used intensively and early.Articolo di analisi • Aug 09
Does Cytosorbents (NASDAQ:CTSO) Have A Healthy Balance Sheet?
NasdaqCM:CTSO 1 Year Share Price vs Fair Value Explore Cytosorbents's Fair Values from the Community and select yours...Articolo di analisi • Jul 02
Further Upside For Cytosorbents Corporation (NASDAQ:CTSO) Shares Could Introduce Price Risks After 54% Bounce
Cytosorbents Corporation ( NASDAQ:CTSO ) shareholders would be excited to see that the share price has had a great...
Nuova narrazione • Apr 11
FDA And Health Canada Decisions Will Advance DrugSorb-ATR Launch
Regulatory decisions on DrugSorb-ATR could drive significant revenue growth, especially in the U.S. and Canada, with a large market opportunity.Articolo di analisi • Jan 17
Further Upside For Cytosorbents Corporation (NASDAQ:CTSO) Shares Could Introduce Price Risks After 28% Bounce
Cytosorbents Corporation ( NASDAQ:CTSO ) shareholders are no doubt pleased to see that the share price has bounced 28...Articolo di analisi • Oct 01
The Market Lifts Cytosorbents Corporation (NASDAQ:CTSO) Shares 43% But It Can Do More
Despite an already strong run, Cytosorbents Corporation ( NASDAQ:CTSO ) shares have been powering on, with a gain of...Articolo di analisi • Jul 04
Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)
With a price-to-sales (or "P/S") ratio of 1.3x Cytosorbents Corporation ( NASDAQ:CTSO ) may be sending bullish signals...Articolo di analisi • Mar 16
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Jan 06
Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper
Unfortunately for some shareholders, the Cytosorbents Corporation ( NASDAQ:CTSO ) share price has dived 28% in the last...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 52 | 5 | N/A | N/A | 1 |
| 12/31/2027 | 47 | 2 | N/A | N/A | 1 |
| 12/31/2026 | 38 | -12 | N/A | N/A | 2 |
| 3/31/2026 | 37 | -12 | -11 | -10 | N/A |
| 12/31/2025 | 37 | -8 | -13 | -12 | N/A |
| 9/30/2025 | 37 | -10 | -10 | -10 | N/A |
| 6/30/2025 | 36 | -10 | -10 | -10 | N/A |
| 3/31/2025 | 35 | -16 | -14 | -13 | N/A |
| 12/31/2024 | 36 | -21 | -15 | -14 | N/A |
| 9/30/2024 | 30 | -20 | -19 | -18 | N/A |
| 6/30/2024 | 30 | -26 | -22 | -21 | N/A |
| 3/31/2024 | 31 | -28 | -24 | -23 | N/A |
| 12/31/2023 | 31 | -29 | -23 | -22 | N/A |
| 9/30/2023 | 37 | -23 | -22 | -21 | N/A |
| 6/30/2023 | 36 | -26 | -24 | -22 | N/A |
| 3/31/2023 | 35 | -31 | -30 | -23 | N/A |
| 12/31/2022 | 35 | -33 | -35 | -28 | N/A |
| 9/30/2022 | 36 | -41 | -36 | -28 | N/A |
| 6/30/2022 | 38 | -36 | -34 | -26 | N/A |
| 3/31/2022 | 41 | -29 | -24 | -20 | N/A |
| 12/31/2021 | 43 | -25 | -18 | -14 | N/A |
| 9/30/2021 | 44 | -16 | -12 | -10 | N/A |
| 6/30/2021 | 45 | -10 | -11 | -9 | N/A |
| 3/31/2021 | 43 | -9 | -7 | -5 | N/A |
| 12/31/2020 | 41 | -8 | -7 | -6 | N/A |
| 9/30/2020 | 36 | -11 | -10 | -9 | N/A |
| 6/30/2020 | 32 | -17 | -12 | -11 | N/A |
| 3/31/2020 | 28 | -18 | -17 | -16 | N/A |
| 12/31/2019 | 25 | -19 | N/A | -17 | N/A |
| 9/30/2019 | 24 | -21 | N/A | -15 | N/A |
| 6/30/2019 | 23 | -17 | N/A | -13 | N/A |
| 3/31/2019 | 23 | -19 | N/A | -13 | N/A |
| 12/31/2018 | 23 | -17 | N/A | -11 | N/A |
| 9/30/2018 | 21 | -15 | N/A | -9 | N/A |
| 6/30/2018 | 19 | -14 | N/A | -8 | N/A |
| 3/31/2018 | 17 | -10 | N/A | -7 | N/A |
| 12/31/2017 | 15 | -9 | N/A | -6 | N/A |
| 9/30/2017 | 14 | -11 | N/A | -7 | N/A |
| 6/30/2017 | 12 | -10 | N/A | -7 | N/A |
| 3/31/2017 | 11 | -11 | N/A | -7 | N/A |
| 12/31/2016 | 10 | -12 | N/A | -7 | N/A |
| 9/30/2016 | 8 | -9 | N/A | -8 | N/A |
| 6/30/2016 | 7 | -10 | N/A | -8 | N/A |
| 3/31/2016 | 6 | -5 | N/A | -8 | N/A |
| 12/31/2015 | 5 | -9 | N/A | -9 | N/A |
| 9/30/2015 | 4 | -17 | N/A | -9 | N/A |
| 6/30/2015 | 4 | -17 | N/A | -9 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che CTSO diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 3.5% ).
Guadagni vs Mercato: Si prevede che CTSO diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.
Guadagni ad alta crescita: Si prevede CTSO diventerà redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di CTSO ( 11.1% all'anno) crescerà più lentamente rispetto al mercato US ( 11.7% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di CTSO ( 11.1% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di CTSO è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/22 11:59 |
| Prezzo dell'azione a fine giornata | 2026/05/22 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Cytosorbents Corporation è coperta da 6 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Sean Lee | H.C. Wainwright & Co. |
| Anthony Petrone | Jefferies LLC |